Veru (STU:FMW0) Short Percentage of Float


STU:FMW0 Veru Inc STU:FMW0
28 GF Score
Price €3.11
! 2 Warning Signs
View Full Analysis

What is Veru Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:FMW0 vs AURX, PDSB, LTRN: Short Percentage of Float Comparison

For the Biotechnology subindustry, Veru's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Veru Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veru's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Veru's Short Percentage of Float falls into.


STU:FMW0
28GF Score
Veru Inc STU:FMW0
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veru Business Description

Other Exchanges VERU:USA
Address 2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
28GF Score

Get the complete analysis for STU:FMW0

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.11
Price